PAS
CAI

Park Avenue Securities’s Caris Life Sciences CAI Stock Holding History

Park Avenue Securities’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$279K Sell
15,680
-12,257
-44% -$219K ﹤0.01% 1564
2026
Q1 		$500K Buy
+27,937
New +$611K ﹤0.01% 1107
2025
Q4 		– Sell
-20,730
Closed -$627K – 1722
2025
Q3 		$627K Buy
+20,730
New +$661K ﹤0.01% 1073

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Park Avenue Securities's CAI Position: Q2 2026 in Review

Park Avenue Securities reduced its Caris Life Sciences (CAI) stake by 44% in Q2 2026, selling an estimated $219K and leaving 15,680 shares worth $279K. The position accounts for ﹤0.01% of the portfolio, ranked #1564.

Park Avenue Securities first reported a position in CAI in Q3 2025 and has held it in 3 quarters since. The position peaked at $627K in Q3 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Park Avenue Securities held 15,680 shares of Caris Life Sciences worth $279K as of Q2 2026.
  • Park Avenue Securities sold 12,257 Caris Life Sciences shares in Q2 2026, an estimated $219K.
  • Caris Life Sciences made up ﹤0.01% of Park Avenue Securities's portfolio in Q2 2026, its #1564 holding.
  • Park Avenue Securities first reported a position in Caris Life Sciences in Q3 2025 and has held it in 3 quarters since.
  • Park Avenue Securities's Caris Life Sciences position peaked at $627K in Q3 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.